Abber Sophie R, Presseller Emily K, Richson Brianne N, Joiner Thomas E, Wierenga Christina E
Department of Psychology, Florida State University, Tallahassee, Florida, USA.
Department of Psychiatry, University of California San Diego Health, San Diego, California, USA.
Int J Eat Disord. 2025 Apr;58(4):748-755. doi: 10.1002/eat.24382. Epub 2025 Jan 20.
Outcomes for low-weight restrictive eating disorders, including anorexia nervosa, restricting type (AN-R) and avoidant/restrictive food intake disorder (ARFID), are sub-optimal. Reducing dietary restriction is a key treatment target. Understanding heterogeneity in patterns of change in dietary restriction may aid in improving outcomes. We examined latent trajectories of change in dietary restriction during treatment and follow-up in AN-R and ARFID.
Adolescents and adults with R-EDs (N = 276, 18% ARFID, 90% female, M = 18) receiving intensive ED treatment completed assessments at five timepoints. Latent growth mixture modeling examined trajectories of change in dietary restriction, measured using the Eating Pathology Symptoms Inventory Restricting subscale. Classes were compared on clinical features at admission to determine characteristics prospectively associated with trajectory.
A 3-class solution emerged: Class 1 comprising individuals with "good response" (n = 138; 33% of those with ARFID in the sample); Class 2 with "good response, rebounding" (n = 81; 41% of ARFID); and Class 3 with "gradual response, low symptoms" (n = 57; 26% of ARFID). Class 3 had lower anxiety and R-ED symptoms than Classes 1 and 2. Class 2 presented with older age than Class 1.
No ARFID-specific classes emerged, underscoring similarities in response to intensive treatment between AN-R and ARFID.
低体重限制性饮食障碍,包括神经性厌食症限制型(AN-R)和回避/限制性食物摄入障碍(ARFID)的治疗效果并不理想。减少饮食限制是关键的治疗目标。了解饮食限制变化模式的异质性可能有助于改善治疗效果。我们研究了AN-R和ARFID患者在治疗及随访期间饮食限制变化的潜在轨迹。
接受强化饮食障碍治疗的患有饮食障碍(R-EDs)的青少年和成年人(N = 276,18%为ARFID,90%为女性,平均年龄18岁)在五个时间点完成评估。潜在增长混合模型研究了使用饮食病理学症状量表限制分量表测量的饮食限制变化轨迹。对各类别在入院时的临床特征进行比较,以确定与轨迹前瞻性相关的特征。
出现了一个三类解决方案:第1类包括“反应良好”的个体(n = 138;样本中ARFID患者的33%);第2类为“反应良好,出现反弹”(n = 81;ARFID患者的41%);第3类为“逐渐反应,症状较轻”(n = 57;ARFID患者的26%)。第3类的焦虑和饮食障碍症状低于第1类和第2类。第2类的年龄比第1类大。
未出现特定于ARFID的类别,这突出了AN-R和ARFID在强化治疗反应方面的相似性。